The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1 ... in studies up to 52 weeks. Also in combination with metformin and ...

Also, sitagliptin has been evaluated in combination with metformin ... in body weight seen after treatment with GLP-1 analogs, DPP-4 inhibitors are body weight neutral. This body weight neutrality ...

Patients who received GLP-1 RAs were compared to those who received dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity score matching, the final analysis included two cohorts of 168,428 ...

People with type 2 diabetes often stick to and continue their treatment when starting oral semaglutide, a GLP-1 receptor agonist, or a DPP-4 inhibitor in real-world settings. Researchers conducted a ...

initiated an SGLT-2 inhibitor or glucagon-like peptide-1 receptor agonist (GLP-1 RA), with a dipeptidyl peptidase-4 (DPP-4) inhibitor as an alternative comparator. After inverse probability of ...

Results We demonstrated that this innovative nanosystem triggers GLP-1 secretion in both human and murine cells as well as in vivo in mice. This strategy increases the endogenous secretion of GLP-1 ...

For patients with comorbid gout, SGLT2 inhibitor use was significantly associated with a 33% lower risk of recurrence and outperformed GLP-1 receptor agonists and DPP-4 inhibitors. The risk for ...

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

Researchers emulated target trials comparing recurrence of nephrolithiasis among patients with preexisting nephrolithiasis initiating SGLT-2 inhibitors vs an active comparator. (HealthDay News ...